{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:13:39Z","timestamp":1767986019494,"version":"3.49.0"},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurol Surg Rep"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nasopharyngeal carcinoma (NPC), a rare head and neck malignancy, arises from the epithelial lining of nasopharyngeal mucosa. The confluence of various risk factors, such as latent Epstein\u2013Barr virus infection, genetic susceptibility, smoking, alcohol consumption, and high nitrosamine diet, is thought to contribute to NPC pathogenesis. Radiation therapy serves as the mainstay of treatment for early stage while concurrent chemotherapy and radiation are the basis of treatment for locoregional advanced disease with overall 80% five-year survival rate. Recurrent or metastatic disease pose treatment challenges as reirradiation, repeat cycles of chemotherapy, and surgery follow with high likelihood of treatment toxicity or postoperative morbidities. Typically reserved for nonresectable recurrent or metastatic disease, immunotherapy serves as novel treatment for NPC. NPC tumor microenvironment predominated by a dense infiltrate of immune cells hosts an ideal target for immunotherapy. Several clinical trials have investigated the efficacy of anti-programmed cell death protein 1 antibodies such as pembrolizumab, nivolumab, and camrelizumab with promising results. Treatment of recurrent and metastatic NPC remains a challenge; however, the advent of immunotherapy has provided additional options and potential for preventative and therapeutic measures.<\/jats:p>","DOI":"10.1055\/a-2148-2429","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T23:00:18Z","timestamp":1691103618000},"page":"e113-e115","source":"Crossref","is-referenced-by-count":4,"title":["Nasopharyngeal Carcinoma: Case Presentation and Literature Review of Treatment Innovation with Immunotherapy"],"prefix":"10.1055","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5609-0717","authenticated-orcid":false,"given":"Somtochi","family":"Okafor","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery and Communication Sciences, Duke University Hospital, Durham, North Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jameel","family":"Muzaffar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical Oncology, Duke University Hospital, Durham, North Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery and Communication Sciences, Duke University Hospital, Durham, North Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan El","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology Head and Neck Surgery, University of California, San Francisco, San Francisco, California, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph Abi","family":"Hachem","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery and Communication Sciences, Duke University Hospital, Durham, North Carolina, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Y P Chen","year":"2019","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2017.01.002","article-title":"Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial","volume":"75","author":"L Chen","year":"2017","journal-title":"Eur J Cancer"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.30566","article-title":"Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA\/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: final results of 2 parallel phase 2 clinical trials","volume":"123","author":"L Kong","year":"2017","journal-title":"Cancer"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/ijc.32099","article-title":"Concurrent chemoradiotherapy with\/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: long-term results of phase 3 randomized controlled trial","volume":"145","author":"W-F Li","year":"2019","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","article-title":"Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial","volume":"119","author":"Q Yang","year":"2019","journal-title":"Eur J Cancer"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1093\/annonc\/mdy249","article-title":"Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study","volume":"29","author":"R L Hong","year":"2018","journal-title":"Ann Oncol"},{"issue":"08","key":"ref7","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/hed.23719","article-title":"Salvage endoscopic nasopharyngectomy and intensity-modulated radiotherapy versus conventional radiotherapy in treating locally recurrent nasopharyngeal carcinoma","volume":"37","author":"X Zou","year":"2015","journal-title":"Head Neck"},{"issue":"10","key":"ref8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/hed.21928","article-title":"Use of a posterior pedicle nasal septum and floor mucoperiosteum flap to resurface the nasopharynx after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma","volume":"34","author":"M Y Chen","year":"2012","journal-title":"Head Neck"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"101890","DOI":"10.1016\/j.ctrv.2019.101890","article-title":"Management of locally recurrent nasopharyngeal carcinoma","volume":"79","author":"A WM Lee","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"K CW Wong","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"36","key":"ref11","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"C Hsu","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"ref12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"B BY Ma","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials","volume":"19","author":"W Fang","year":"2018","journal-title":"Lancet Oncol"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"A TC Chan","year":"2023","journal-title":"Ann Oncol"},{"issue":"01","key":"ref15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/cac2.12248","article-title":"JUPITER-02 trial: advancing survival for recurrent metastatic nasopharyngeal carcinoma and next steps","volume":"42","author":"L LY Tan","year":"2022","journal-title":"Cancer Commun (Lond)"},{"issue":"09","key":"ref16","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"H Q Mai","year":"2021","journal-title":"Nat Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"104640","DOI":"10.1016\/j.oraloncology.2020.104640","article-title":"The efficacy and safety of PD-1\/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: a systematic review and meta-analysis","volume":"104","author":"B-C Wang","year":"2020","journal-title":"Oral Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1079515","DOI":"10.3389\/fimmu.2022.1079515","article-title":"Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma","volume":"13","author":"W Li","year":"2023","journal-title":"Front Immunol"},{"issue":"23","key":"ref19","first-page":"6952","article-title":"Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma","volume":"62","author":"C L Lin","year":"2002","journal-title":"Cancer Res"}],"container-title":["Journal of Neurological Surgery Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2148-2429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T22:40:38Z","timestamp":1696372838000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2148-2429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":19,"aliases":["10.1055\/s-0043-1774333"],"journal-issue":{"issue":"03","published-online":{"date-parts":[[2023,7,13]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2148-2429","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["2193-6358","2193-6366"],"issn-type":[{"value":"2193-6358","type":"print"},{"value":"2193-6366","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,3]]},"published":{"date-parts":[[2023,7]]}}}